Lung cancer stands out among the most frequent and poorly prognostic tumors in advanced societies. Despite the molecular advances of recent years, our understanding of the cellular changes that lead to this pathology and the sensitivities of tumor cells with therapeutic use is still limited. In this project, we intend to combine the efforts of Physics and Cell Biology with preclinical and clinical advances to advance both in the understanding and the therapeutic proposals in this disease.
The iLUNG Program aims to develop and apply for the first time novel techniques of nanotechnology from a perspective of molecular and cellular biology in which clinical samples can be diagnosed and stratified molecularly based on their genomic alterations. On the other hand, preclinical models will be used in genetically modified mice to evaluate possible therapies directed against such genomic alterations, especially in the oncogenic pathway that drives the cellular signals from the membrane receptors, to the Ras oncogenes and to cell cycle regulators, as well as its implications in immunotherapy. To this end, the objectives of the iLUNG Program will focus on:
a) development of new molecular diagnostic methods based on nanotechnology.
b) stratification of molecular alterations based on massive genomic studies in patients.
c) in vivo evaluation of new therapeutic strategies directed to groups of patients with specific alterations.
Five research groups belonging to the Spanish national Cancer Research Centre, National Microelectronics Center, Complutense University-Hospital 12 de Octubre and HM Sanchinarro University Hospital will participate in this combined effort against lung cancer.